Cullinan Therapeutics, Inc. announced updated Phase 1 OUTRACE clinical trial data for CLN-978 in patients with rheumatoid arthritis and systemic lupus erythematosus. In the rheumatoid arthritis cohort, a patient achieved DAS28-ESR remission at week eight. The company also shared initial Phase 1b/2a data for velinotamig in China, where two patients achieved complete renal response and significant reductions in SLEDAI-2K scores. Cullinan Therapeutics, Inc. is a biotechnology company focused on developing immunology-related therapies.
